Submitted by dcc on Fri, 2019-06-14 08:35 Study Title: A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# TBD) in Children with Relapsed, Refractory or Progressive NeuroblastomaCIRB: Pediatric CIRBLead Group: COGStatus: ActiveReview Status: Available to Open
